Medpace shares declined by approximately 1.27% in the latest trading session, underperforming the broader market’s flat performance. Trading volume was modestly above the 30-day average, signaling that some investors may have taken profits after recent gains. The pullback follows a multi-week advance driven by stronger-than-expected third-quarter results and upward revisions to full-year guidance.

In the third quarter, Abacus FCF Advisors LLC boosted its Medpace holdings by 23.4%, acquiring an additional 3,917 shares to reach a total position of 20,663 shares valued at around $10.6 million. Other large asset managers also raised stakes: Wasatch Advisors LP added 14.0%, Mawer Investment Management Ltd. increased its position by 17.4%, AQR Capital Management LLC by 15.1%, TD Asset Management Inc. by 15.6%, and Epoch Investment Partners Inc. by 11.4%. Collectively, institutional ownership now stands at nearly 78% of the company’s outstanding stock, underscoring confidence among professional investors.

Company insiders have accelerated selling in recent months. Vice President Susan E. Burwig sold 20,000 shares for a transaction totaling approximately $12.2 million, reducing her ownership by over 40%. Chief Executive Officer August J. Troendle disposed of 59,025 shares in a trade valued at roughly $35.9 million, trimming his stake by around 7%. Over the past 90 days, insiders have offloaded 387,925 shares with a combined value near $233.4 million, while insider ownership remains at about 20.3% of the stock.

Analyst sentiment is mixed, with one firm maintaining a strong-buy stance, two issuing buy recommendations, ten assigning holds and four expressing sell views. The consensus target implies modest upside versus current levels. Recent research notes include an upgrade to neutral by Rothschild & Co Redburn following a target increase, an outperform call from Mizuho after raising its price objective, and a hold recommendation from Wall Street Zen. Forecasts include full-year earnings guidance in a range that suggests mid-teens growth in per-share profits for fiscal 2025.